Increased serum YKL-40 in patients with pulmonary sarcoidosis - a potential marker of disease activity?

被引:85
作者
Johansen, JS
Milman, N
Hansen, M
Garbarsch, C
Price, PA
Graudal, N
机构
[1] Univ Copenhagen, Herlev Hosp, Dept Rheumatol, DK-1168 Copenhagen, Denmark
[2] Univ Copenhagen, Hvidovre Hosp, Dept Rheumatol, DK-1168 Copenhagen, Denmark
[3] Univ Copenhagen, Rigshosp, Div Lung Transplantat, Dept Med B, DK-1168 Copenhagen, Denmark
[4] Univ Copenhagen, Panum Inst, Inst Med Anat, Sect A, DK-1168 Copenhagen, Denmark
[5] Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA
关键词
39 kDa heparin binding protein; YKL; 40; CHI3L1; giant cells; pulmonary fibrosis; pulmonary sarcoidosis;
D O I
10.1016/j.rmed.2004.09.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: YKL-40, a growth factor for fibroblasts and vascular endothelial cells, is secreted by macrophages and neutrophils. Elevated serum YKL-40 is found in patients with diseases characterized by inflammation, tissue remodelling and ongoing fibrosis. The aim was to evaluate whether macrophages and giant cells in the granulomatous sarcoid lesions of patients with pulmonary sarcoidosis produce YKL-40 and to determine whether serum YKL-40 in these patients were associated with disease activity. Methods: Serum YKL-40 was determined by radioimmunoassay in 27 patients with a histological diagnosis of pulmonal sarcoidosis. Immunohistochemical staining for YKL-40 antigen was performed in five biopsies with pulmonary sarcoid lesions. Serum YKL-40 was likewise measured in 173 healthy age-matched control subjects. Results: Mononuclear cells/macrophages and giant cells in pulmonary sarcoid granulomas expressed YKL-40 protein. Serum YKL-40 was higher in patients with pulmonary sarcoidosis compared to controls (P < 0.001) and 63% had elevated serum YKL-40. There was a positive correlation between serum YKL-40 and serum angiotensin converting enzyme (rho = 0.55, P = 0.0053). Patients with serum YKL40 > median value in the patient group had lower carbon monoxide diffusion capacity corrected for alveolar volume (DLCO/VA) than patients with serum YKL-40 <= the median value (P = 0.015). Conclusions: Serum YKL-40 may be a novel biomarker of sarcoid disease activity and ongoing fibrosis in patients with pulmonary sarcoidosis. (c) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:396 / 402
页数:7
相关论文
共 52 条
[51]   Cellular immune response to human cartilage glycoprotein-39 (HC gp-39)-derived peptides in rheumatoid arthritis and other inflammatory conditions [J].
Vos, K ;
Miltenburg, AMM ;
van Meijgaarden, KE ;
van den Heuvel, M ;
Elferink, DG ;
van Galen, PJM ;
van Hogezand, RA ;
van Vliet-Daskalopoulou, E ;
Ottenhoff, THM ;
Breedveld, FC ;
Boots, AMH ;
de Vries, RRP .
RHEUMATOLOGY, 2000, 39 (12) :1326-1331
[52]   Heterogeneity of human blood monocytes: The CD14(+)CD16(+) subpopulation [J].
ZieglerHeitbrock, HWL .
IMMUNOLOGY TODAY, 1996, 17 (09) :424-428